← Leaderboards
Daniel J. Powell
University Of Pennsylvania
$8,015,334
Attributed
$10,765,642
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,765,642 · 5
By mechanism
R01$7,476,660 · 3
UG3$2,906,182 · 1
R21$382,800 · 1
Top collaborators
- Michael David Farwell6 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Stephen G Emerson$28,932,839
- Carl H. June$35,377,952
- James L Riley$56,591,102
- Peter J O'Dwyer$138,294,037
- Mitchell D Schnall$128,628,301
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoAntigensT-LymphocyteLigandsTumorMediatingResponseChimeric Antigen ReceptorDoseCancer CellDesignSpecificityMalignant NeoplasmsDockingAntibodiesAntigen TargetingImmunologic ReceptorsGenerationsInfusion ProceduresTumor AntigensGene TherapyTumor SpecificityT Cell TherapyEngineering
Grant awards (17)
Dual-targeted DOTA CAR T cells with image-guided monitoring for solid tumor treatment$1,453,091
UG3 · FY2025 · CA · contact PI
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer$1,300,301
R01 · FY2025 · CA · contact PI
Dual-targeted DOTA CAR T cells with image-guided monitoring for solid tumor treatment$1,453,091
UG3 · FY2024 · CA · contact PI
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer$626,526
R01 · FY2024 · CA · contact PI
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer$652,287
R01 · FY2023 · CA · contact PI
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer$672,991
R01 · FY2022 · CA · contact PI
Quantitative control of CAR T cells via image-guided delivery and monitoring$638,831
R01 · FY2021 · EB · contact PI
Quantitative control of CAR T cells via image-guided delivery and monitoring$651,868
R01 · FY2020 · EB · contact PI
Quantitative control of CAR T cells via image-guided delivery and monitoring$651,868
R01 · FY2019 · EB · contact PI
Quantitative control of CAR T cells via image-guided delivery and monitoring$651,868
R01 · FY2018 · EB · contact PI
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer$332,000
R01 · FY2016 · CA · contact PI
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer$332,000
R01 · FY2015 · CA · contact PI
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer$322,040
R01 · FY2014 · CA · contact PI
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer$312,080
R01 · FY2013 · CA · contact PI
A Universal Approach to Personalized Adoptive T cell Therapy of Cancer$332,000
R01 · FY2012 · CA · contact PI
Tailored antigen specificity for personalized adoptive T cell therapy of cancer$208,800
R21 · FY2012 · CA · contact PI
Tailored antigen specificity for personalized adoptive T cell therapy of cancer$174,000
R21 · FY2011 · CA · contact PI